コンテンツへスキップ
Merck

GF54212914

ランタン

foil, not light tested, 100x100mm, thickness 0.025mm, as rolled, 99%

別名:

ランタン

ログイン組織・契約価格を表示する


About This Item

実験式(ヒル表記法):
La
CAS番号:
分子量:
138.91
MDL番号:
UNSPSCコード:
12141607
PubChem Substance ID:
NACRES:
NA.23

アッセイ

99%

形状

foil

メーカー/製品名

Goodfellow 542-129-14

抵抗性

54 μΩ-cm

サイズ×厚み

100x100 mm × 0.025 mm

bp

3464 °C (lit.)

mp

920 °C (lit.)

密度

6.19 g/mL at 25 °C (lit.)

SMILES記法

[La]

InChI

1S/La

InChI Key

FZLIPJUXYLNCLC-UHFFFAOYSA-N

類似した製品をお探しですか? 訪問 製品比較ガイド

関連するカテゴリー

詳細

For updated SDS information please visit www.goodfellow.com.

法的情報

Goodfellow製品

保管分類コード

4.3 - Hazardous materials which set free flammable gases upon contact with water

WGK

WGK 3

引火点(°F)

Not applicable

引火点(℃)

Not applicable


試験成績書(COA)

製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Stuart M Sprague
Current medical research and opinion, 23(12), 3167-3175 (2007-11-10)
Obstacles to successful management of hyperphosphatemia in chronic kidney disease include inadequate control of dietary phosphate and non-compliance with phosphate-binder therapy. Three major classes of phosphate binders include calcium-based binders, sevelamer HCl, and lanthanum carbonate. A literature search was performed
Amy Barton Pai et al.
Expert opinion on drug metabolism & toxicology, 5(1), 71-81 (2009-02-25)
Hyperphosphatemia is recognized as a principal mineral disorder in chronic kidney disease (CKD) that leads to the development of secondary hyperparathyroidism. Recent data indicate that hyperphosphatemia is associated with accelerated cardiac calcification and increased mortality in patients with CKD. Control
Marc E De Broe
Seminars in dialysis, 21(2), 142-144 (2008-02-06)
The recent recognition of gadolinium (Gd) administration as a cause of nephrogenic systemic fibrosis (NSF) is a growing concern. The similarity of Gd and lanthanum (La), based on their place in the table of Mendeljev, has led to assumptions that
Mario Cozzolino et al.
Expert opinion on pharmacotherapy, 13(16), 2337-2353 (2012-10-05)
High phosphate levels are associated with unfavorable outcomes in ESRD. Recent data suggested that phosphate levels within the normal range are equally associated with poor outcomes in the community and CKD stage 3 - 4. Several concept papers support the
Declan de Freitas et al.
Seminars in dialysis, 20(4), 325-328 (2007-07-20)
Hyperphosphatemia is associated with increased morbidity and mortality in dialysis patients. Oral phosphate binders are necessary to control serum phosphate in patients eating a normal diet and undergoing peritoneal dialysis or thrice weekly hemodialysis. Until recently, none of the available

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)